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Acremonium spp. are ﬁlamentous, cosmopolitan fungi commonly isolated from plant debris and soil. They are infrequent
pathogens in humans. Acremonium fungemia has been reported in neutropenic patients associated with central venous catheters
andinnonneutropenicpatientsreceivinglong-termtotalparenteralnutrition.TNF-αblockadeisassociatedwithfungalinfections,
but no Acremonium spp. infection had been reported up to the present. In this paper, we present a patient with ulcerative colitis
who developed Acremonium kiliense fungemia associated with inﬂiximab therapy while receiving total parenteral nutrition. The
patientwassuccessfullytreatedwithvoriconazole.Acremoniumsp.infectionmustbesuspectedasanothercauseoffungalinfection
in patients under treatment with inﬂiximab.
1.Introduction
InﬂiximabisachimericIgG1κmonoclonalantibodyusedfor
the treatment of bowel inﬂammatory diseases, rheumatoid
arthritis, and psoriasis. Inﬂiximab binds to the soluble and
transmembrane forms of tumor necrosis factor-α (TNF-α)
receptors, neutralizing the biologic activity of TNF-α.T N F - α
blockade is associated with invasive fungal infections [1].
In this paper, we report a patient with ulcerative colitis
(UC) who developed Acremonium kiliense catheter-related
fungemia associated with inﬂiximab therapy while receiving
t o t a lp a r e n t e r a ln u t r i t i o n .
2. Case Presentation
A30-year-oldmalepatientwasadmittedbecauseofdiarrhea.
He had a history of 14-month UC treated with mesalamine,
glucocorticoids, cyclosporine, and 6-mercaptopurine (6-
MP). When he was admitted, he was only on prednisone and
6-MP. Pancolitis was revealed by total colonoscopy. Despite
glucocorticoidand6-MPdoseescalation,diarrheaincreased.
Total parenteral nutrition was started. Fever developed.
Blood and urine cultures were negative. Clostridium diﬃcile
toxins (stool) and early cytomegalovirus antigen (stool and
blood) werenegative. Fluconazole wasstarted upon evidence
of Candida sp. growth in stool culture. The central venous
catheter (CVC) was removed. The CVC tip culture was neg-
ative,andanewCVCwasinserted.CTscandidnotrevealany
pulmonary inﬁltrates or intraabdominal abscess. Fever was
assumed to originate from UC activity. Inﬂiximab therapy
(5mg/kg) was initiated. The patient received two doses of in-
ﬂiximab (days 0 and 14). Diarrhea and fever continued. A
total colonoscopy was performed 24 days after the ﬁrst dose
of inﬂiximab. No improvement was recorded.
Peripheral vein and CVC blood samples were cultured si-
multaneously. Acremonium kiliense was isolated in CVC
blood samples more than 2 hours earlier than isolation from
peripheral blood cultures. Catheter related fungemia was
diagnosed.
The CVC was removed, and intravenous voriconazole
(6mg/kg bid on the ﬁrst day and then 4mg/kg bid) was
initiated.Bloodculturesafter7daysoftherapywerenegative.
A total colectomy, an ileostomy, and a mucous ﬁstula were
performed. The patient was discharged with oral prednisone
and rectal budesonide. Oral voriconazole treatment was con-
tinued until glucocorticoids ended.2 Case Reports in Infectious Diseases
3. Discussion
Acremonium spp. are ﬁlamentous, cosmopolitan fungi typi-
cally isolated from plant debris and soil. However, they are
infrequent pathogens in humans. In normal hosts, Acremo-
nium sp. is the causative agent of eumycotic white grain myc-
etoma, onychomycosis, keratitis, endophthalmitis, peritoni-
tis, whereas in immunocompromised hosts, it has been re-
ported to cause catheter related infections, pneumonia, en-
docarditis, meningitis, brain abscesses and osteomyelitis [2].
In 1991, Fincher et al. reviewed case reports including Acre-
moniuminfectionsandclassiﬁedthemas(1)allergic,(2)col-
onizing, (3) superﬁcial/locally invasive, (4) ocular, (5) myc-
etoma,(6)invasivepulmonary,or(7)disseminated[3].Acre-
monium infections in immunocompromised patients appear
to be rare. In patients with hematological malignancies,
Acremonium was isolated in only one of 391 cases of ﬁl-
amentous fungi infections over a ten-year term [4].
Acremonium fungemia associated with CVC has been
reported in neutropenic patients and in nonneutropenic pa-
tients receiving long-term total parenteral nutrition [5–8].
We have not found any Acremonium fungemia reports
in association with inﬂiximab, but fungal infections with
TNF-α blockers have been well described. Tsiodras et al.
reviewed 226 mycoses associated with inﬂiximab, most of
which were caused by Histoplasma sp. (n:72), Candida sp.
(n:54), Aspergillus sp. (n:48), Coccidioides sp. (n:27), and
Cryptococcus sp. (n:17) [1]. None of them had been caused
by Acremonium sp [1]. In the patient reported in this paper,
A. kiliense was isolated 24 days after the ﬁrst dose of inﬂix-
imab. Mycoses associated with inﬂiximab usually appear at
a median of 55 days after initiation of therapy, but the in-
terquartile range is between 15 and 140 days [1].
Successful treatment of Acremonium fungemia with vor-
iconazole was reported by Mattei et al. [9].
Recommendations have been published to reduce the
infection risk with the use of TNF-α blockers [10]. Recently,
a European Consensus has alerted about the low-frequency
but high mortality rate of patients with inﬂammatory bowel
diseases who are under immunomodulatory treatments and
develop fungal infections. This Consensus has advised that
when a fungal or parasitic infection occurs, TNF-α blockers
must be withdrawn. These agents may be reintroduced in
conjunction with secondary chemoprophylaxis [11].
This seems to be the ﬁrst case of A. kiliense fungemia in
a UC patient receiving inﬂiximab. Acremonium sp. infection
must be suspected as another cause of fungal infection in
patients under inﬂiximab treatment.
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